Naoko Takebe

12.1k total citations · 4 hit papers
181 papers, 7.4k citations indexed

About

Naoko Takebe is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Naoko Takebe has authored 181 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Molecular Biology, 75 papers in Oncology and 40 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Naoko Takebe's work include Cancer Genomics and Diagnostics (27 papers), Hedgehog Signaling Pathway Studies (25 papers) and Epigenetics and DNA Methylation (15 papers). Naoko Takebe is often cited by papers focused on Cancer Genomics and Diagnostics (27 papers), Hedgehog Signaling Pathway Studies (25 papers) and Epigenetics and DNA Methylation (15 papers). Naoko Takebe collaborates with scholars based in United States, Japan and Malaysia. Naoko Takebe's co-authors include S. Percy Ivy, Pamela Jo Harris, Ronald Q. Warren, Sherry X. Yang, Joseph Clara, Yingzi Yang, Cecilia Monge, Hideaki Bando, Lucio Miele and Woondong Jeong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Naoko Takebe

168 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

2015 988 citations Naoko Takebe et al. profile →
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways

2010 792 citations Naoko Takebe et al. profile →
Principles and Current Strategies for Targeting Autophagy for Cancer Treatment

2011 728 citations Naoko Takebe et al. Clinical Cancer Research profile →
Targeting signalling pathways and the immune microenvironment of cancer stem cells — a clinical update

2019 538 citations Naoko Takebe et al. profile →

Peers

Countries citing papers authored by Naoko Takebe

Since Specialization

Citations

This map shows the geographic impact of Naoko Takebe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoko Takebe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoko Takebe more than expected).

Fields of papers citing papers by Naoko Takebe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoko Takebe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoko Takebe. The network helps show where Naoko Takebe may publish in the future.

Co-authorship network of co-authors of Naoko Takebe

This figure shows the co-authorship network connecting the top 25 collaborators of Naoko Takebe. A scholar is included among the top collaborators of Naoko Takebe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoko Takebe. Naoko Takebe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types 2025 ·Cancer Research Communications ·(unknown), Thomas S. Dexheimer, Nathan P. Coussens, (unknown), Raymond G. Fox, Samantha B. Kemp, Poorva Juneja, Joel Morris, Melinda G. Hollingshead, Naoko Takebe, James H. Doroshow, Beverly A. Teicher	0
2	Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors 2025 ·JCO Precision Oncology ·Geraldine O’Sullivan Coyne, T. Khanh, Shivaani Kummar, Sarina A. Piha‐Paul, Larry Rubinstein, Robert J. Kinders, Ralph E. Parchment, Deborah Wilsker, Katherine V. Ferry‐Galow, Brandon Miller, Naoko Takebe, Lamin Juwara, (unknown), Ashley Bruns, (unknown), Abdul Rafeh Naqash, Arjun Mittra, Andrea Regier Voth, James H. Doroshow, (unknown)	0
3	Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study 2025 ·Cancer Research Communications ·William C. Reinhold, Elisabetta Marangoni, Fathi Elloumi, Rémi Montagne, Sudhir Varma, (unknown), Keyvan Rezaï, (unknown), Ahmed Dahmani, Rania El Botty, Léa Huguet, (unknown), Naoko Takebe, Samuel Huguet, Augustin Luna, Yves Pommier	1
4	The Novel ATR Inhibitor Tuvusertib (M1774) Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs 2024 ·Molecular Cancer Therapeutics ·Ukhyun Jo, Yasuhiro Arakawa, Astrid Zimmermann, Daiki Taniyama, (unknown), Lisa M. Jenkins, Tapan K. Maity, Suresh Kumar, Frank T. Zenke, Naoko Takebe, Yves Pommier	10
5	Pilot study of CBX-12 pharmacodynamics in patients with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·(unknown), Geraldine O’Sullivan Coyne, Larry Rubinstein, Naoko Takebe, John Joseph Wright, Deborah Wilsker, Katherine V. Ferry‐Galow, Chris Karlovich, Larry Anderson, (unknown), Ralph E. Parchment, James H. Doroshow, (unknown)	1
6	Molecular profiling of plasma from matched NCI-MATCH gynecological cancers. 2024 ·Journal of Clinical Oncology ·(unknown), Bao T. Le, (unknown), (unknown), Rini Pauly, Li Chen, (unknown), (unknown), Lyndsay N. Harris, Alice P. Chen, Naoko Takebe, Traci Pawlowski, (unknown), Peter J. O’Dwyer, James H. Doroshow, (unknown), Biswajit Das, Chris Karlovich	0
7	Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4 2024 ·Cancer Research Communications ·(unknown), Christophe E. Redon, Liton Kumar Saha, Andy D. Tran, Anjali Dhall, Robin Sebastian, Daiki Taniyama, Michael J. Kruhlak, William C. Reinhold, Naoko Takebe, Yves Pommier	4
8	A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2 - Altered Advanced Solid Tumor Malignancies (NCI 10170) 2024 ·Cancer Research Communications ·(unknown), W. Kimryn Rathmell, Geoffrey I. Shapiro, Naoko Takebe, Jordi Rodón, Devalingam Mahalingam, Nikolaos A. Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A. Boerner, (unknown), Gregor Krings, Timothy F. Burns, Emily K. Bergsland, Pamela N. Münster, Alan Ashworth, Patricia LoRusso, Rahul Aggarwal	6
9	Current landscape of targeted therapy in esophageal squamous cell carcinoma 2024 ·Current Problems in Cancer ·(unknown), Daisuke Kotani, Takashi Kojima, Naoko Takebe, Kohei Shitara	2
10	Rethinking Oncologic Treatment Strategies with Interleukin-2 2023 ·Cells ·Brian Ko, Naoko Takebe, (unknown), Monish Ram Makena, Alice P. Chen	14
11	Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification 2022 ·Journal of Clinical Oncology ·Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony Elias, Richard D. Carvajal, Thomas J. George, Ying Yuan, (unknown), Shannon N. Westin, (unknown), Ecaterina E. Dumbrava, Daniel D. Karp, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Jordi Rodón, Naoko Takebe, Karen H. Lu, Khandan Keyomarsi, Funda Meric‐Bernstam	50
12	SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243 2021 ·Cancer Research ·Yasuhisa Murai, Ukhyun Jo, Junko Murai, Lisa M. Jenkins, Shar-yin N. Huang, Sirisha Chakka, Lu Chen, Ken Cheng, Shinsaku Fukuda, Naoko Takebe, Yves Pommier	33
13	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903) 2020 ·Clinical Cancer Research ·Erin M. Bertino, Ryan D. Gentzler, (unknown), Jill Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, (unknown), Jyoti Malhotra, Liza C. Villaruz, Cloud P. Paweletz, Christie J. Lau, Lynette M. Sholl, Naoko Takebe, Jeffrey A. Moscow, Geoffrey I. Shapiro, Pasi A. Jänne, Geoffrey R. Oxnard	31
14	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab 2016 ·Clinical Cancer Research ·Sandra P. D’Angelo, Alexander N. Shoushtari, Mary Louise Keohan, Mark A. Dickson, Mrinal M. Gounder, Ping Chi, Jennifer K. Loo, (unknown), (unknown), (unknown), Joseph P. Erinjeri, Mark J. Bluth, (unknown), Howard Streicher, Naoko Takebe, Li‐Xuan Qin, Cristina R. Antonescu, Ronald P. DeMatteo, Richard D. Carvajal, William D. Tap	98
15	Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use 2015 ·Clinical Cancer Research ·Apurva K. Srivastava, (unknown), (unknown), Melinda G. Hollingshead, (unknown), (unknown), Jeevan Prasaad Govindharajulu, (unknown), Dominic Esposito, James P. Mapes, Robert J. Kinders, Naoko Takebe, Joseph E. Tomaszewski, Shivaani Kummar, James H. Doroshow, Ralph E. Parchment	19
16	National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network 2014 ·American Society of Clinical Oncology Educational Book ·Jeffrey S. Abrams, Barbara A. Conley, Margaret Mooney, James A. Zwiebel, Alice P. Chen, John J. Welch, Naoko Takebe, Shakun Malik, Lisa M. McShane, Edward L. Korn, Mickey Williams, Louis M. Staudt, James H. Doroshow	122
17	Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma 2014 ·Clinical Cancer Research ·Edward Kim, Vaibhav Sahai, Ethan V. Abel, Kent A. Griffith, Joel K. Greenson, Naoko Takebe, Gazala Khan, John Blau, Ronald A. Craig, Ulysses J. Balis, Mark M. Zalupski, Diane M. Simeone	236
18	Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study 2013 ·Clinical Cancer Research ·Amar Gajjar, Clinton F. Stewart, David W. Ellison, Sue C. Kaste, Larry E. Kun, Roger J. Packer, Stewart Goldman, Murali Chintagumpala, Dana Wallace, Naoko Takebe, James M. Boyett, Richard J. Gilbertson, Tom Curran	164
19	RCAS/SCL-TVA Animal Model Allows Targeted Delivery of Polyoma Middle T Oncogene to Vascular Endothelial Progenitors In vivo and Results in Hemangioma Development 2008 ·Clinical Cancer Research ·(unknown), Alfredo A. Molinolo, Xiangfei Cheng, Jon Frampton, Naoko Takebe, J. Silvio Gutkind, Ricardo A. Feldman	7
20	Autologous stem cell transplantation (ASCT) followed by consolidation chemotherapy for multiple myeloma (MM) 2000 ·Blood ·Ivana Gojo, (unknown), (unknown), Guido Tricot, R. G. Fenton, (unknown), BR Meisenberg, Naoko Takebe, Stanley R. Frankel, C Sarkodee-Adoo, Meyer R. Heyman, Kathleen Ruehle, Roger Smith, (unknown), Aaron P. Rapoport	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact